Single and Repeated Doses of EGb 761^® do not Affect Pharmacokinetics or Pharmacodynamics of Rivaroxaban in Healthy Subjects.

ABSTRACT: The present drug-drug interaction study investigates whether single or repeated doses of 240 mg Ginkgo biloba extract EGb 761^® alter the pharmacokinetics or pharmacodynamics of rivaroxaban in healthy subjects. This was a single-centre, two-period, fixed-sequence trial. In Period 1, rivaroxaban was taken alone. In Period 2, rivaroxaban was given on the first and last of 8 days of EGb 761^® treatment. Plasma concentrations of rivaroxaban and anti-Factor Xa activity were determined until 48 h after each rivaroxaban intake. The data of forty-one healthy subjects (25 males, 16 females) aged 21-70 years were evaluable. Geometric mean ratios (90% confidence intervals) for rivaroxaban administered concomitantly with a single or multiple doses of EGb 761^® vs.

SUBMITTER: Hoerr R 

PROVIDER: S-EPMC9065292 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature